Active substance
Formoterol
- US FDA 14
- Health Canada 2
- US price lines 4
- NHS prices 4
- Safety 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PERFOROMIST | 0.02MG/2ML | solution · inhalation | VIATRIS SPECIALTY | Prescription | 11 May 2007 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | TEVA PHARMS USA INC | Prescription | 22 Jun 2021 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | ALEMBIC | Prescription | 22 Nov 2021 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | LUPIN | Prescription | 22 Aug 2022 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | RITEDOSE CORP | Prescription | 25 Nov 2022 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | WILSHIRE PHARMS INC | Prescription | 13 Dec 2022 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | MANKIND PHARMA | Prescription | 22 Mar 2023 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | MICRO LABS | Prescription | 26 Jun 2024 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | LEXENPHARM | Prescription | 22 Oct 2024 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | DR REDDYS | Prescription | 30 Jan 2025 |
| FORMOTEROL FUMARATE | 0.02MG/2ML | solution · inhalation | DEVA HOLDING AS | Prescription | 11 Feb 2025 |
| FORADIL | 0.012MG/INH **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | powder · inhalation | NOVARTIS | Discontinued | 16 Feb 2001 |
| FORADIL | 0.012MG/INH | powder · inhalation | NOVARTIS | Discontinued | 25 Sep 2001 |
| FORADIL CERTIHALER | 0.0085MG/INH | powder · inhalation | NOVARTIS | Discontinued | 15 Dec 2006 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| OXEZE TURBUHALER | 02237224 | 12 MCG / ACT | POWDER · INHALATION | ASTRAZENECA CANADA INC |
| OXEZE TURBUHALER | 02237225 | 6 MCG / ACT | POWDER · INHALATION | ASTRAZENECA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FORMOTEROL 20 MCG/2 ML NEB VL | $1.33557 | per ML | 23 Sep 2026 |
| US NADAC | FORMOTEROL 20 MCG/2 ML NEB VL | $1.27321 | per ML | 23 Sep 2026 |
| US NADAC | PERFOROMIST 20 MCG/2 ML SOLN | $10.04859 | per ML | 1 Jan 2026 |
| US NADAC | PERFOROMIST 20 MCG/2 ML SOLN | $10.1156 | per ML | 1 Jan 2026 |
| NHS Drug Tariff | Formoterol 12micrograms/dose dry powder inhaler | £24.80 | 60 dose | 1 Oct 2026 |
| NHS Drug Tariff | Formoterol 12micrograms/dose dry powder inhaler | £23.75 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Formoterol 12micrograms/dose inhaler CFC free | £30.06 | 100 dose | 1 Oct 2026 |
| NHS Drug Tariff | Formoterol 6micrograms/dose dry powder inhaler | £24.80 | 60 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 27 Apr 2026 BREZTRI AEROSPHERE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Apr 2026 SYMBICORT AEROSPHERE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Nov 2020 BEVESPI AEROSPHERE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Aug 2019 DULERA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 May 2019 PERFOROMIST — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Dec 2017 SYMBICORT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Formoterol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.